Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis

Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation

(2022) Paula Muñiz et al.   Frontiers in Immunology

Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis

(2020) Doaa H. S. Attia et al.   CLINICAL RHEUMATOLOGY

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

(2016) Gareth J. Veal et al.   EUROPEAN JOURNAL OF CANCER

Con: Cyclophosphamide for the treatment of lupus nephritis

(2016) Chi Chiu Mok   NEPHROLOGY DIALYSIS TRANSPLANTATION

CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide

(2016) Rania M. Labib et al.   PLoS One

Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma

(2015) Veronika Bachanova et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Genetic markers inCYP2C19andCYP2B6for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus

(2015) Wenying Shu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Mycophenolate mofetil for lupus nephritis: an update

(2015) Chi Chiu Mok   Expert Review of Clinical Immunology

Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation

(2015) Ibrahim El-Serafi et al.   PLoS One

Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations

(2014) Jeong-Hyun Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation

(2014) María José Martínez-Bravo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

(2013) G. G. Johnson et al.   BLOOD

Using cyclophosphamide in inflammatory rheumatic diseases

(2013) Tobias Brummaier et al.   European Journal of Internal Medicine

Overview of lupus nephritis management guidelines and perspective from Asia

(2013) Chi Chiu Mok et al.   NEPHROLOGY

Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy

(2013) Sarah C. Preissner et al.   PLoS One

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides

(2011) Guillaume Le Guenno et al.   ARTHRITIS AND RHEUMATISM

Q172H Replacement Overcomes Effects on the Metabolism of Cyclophosphamide and Efavirenz Caused by CYP2B6 Variant with Arg262

(2011) N. Ariyoshi et al.   DRUG METABOLISM AND DISPOSITION

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

(2010) J Bray et al.   BRITISH JOURNAL OF CANCER

Cyclophosphamide and cancer: golden anniversary

(2009) Ashkan Emadi et al.   Nature Reviews Clinical Oncology

Drug Focus: Pharmacogenetic studies related to cyclophosphamide-based therapy

(2009) Navin Pinto et al.   PHARMACOGENOMICS

Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia

(2008) V Rocha et al.   LEUKEMIA

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

(2008) Corine Ekhart et al.   Pharmacogenetics and Genomics